Table 4.

Cost-effectiveness results for a cohort of 1000 patients, where the percentage of placebo patients returning for PCI within 1 year is varied

Scenario: per cent crossing over from placebo	Total costs	Total QALYs	Cost difference*	QALY difference*	ICER†
20	£740 538	797.87	£1 254 880	15.791	£79 469
40	£1 070 460	799.815	£924 958	13.846	£66 804
60	£1 399 549	802.023	£595 869	11.637	£51 203
80	£1 725 707	804.751	£269 711	8.91	£30 271

*Compared with the PCI group.

†ICER calculated prior to rounding.

ICER, incremental cost-effectiveness ratio; PCI, percutaneous coronary intervention; QALYs, quality-adjusted life-years.